Dear Valued Customers, Patients and Industry Partners:
It’s an extraordinary time for our world and our industry as COVID-19 reaches pandemic levels. Our thoughts are with those who have been impacted and the entire drug development community as we focus on a solution for this worldwide crisis.
To navigate this challenging environment, Parexel has a robust global pandemic response effort in place led by members of our Executive Leadership Team and guided by our Chief Medical and Scientific Officer. As this situation evolves we continue to monitor in real time and align with guidance from the World Health Organization, the Centers for Disease Control (CDC) and local government authorities while working in coordination with our investigative sites to ensure the continuity of your projects on time and at the highest standards of quality.
We have the experts, innovations and processes in place to navigate the new and rapidly changing landscape while keeping the patient at the heart of everything we do. Our teams are deploying remote qualification visits and monitoring along with best practices in risk-based monitoring surveillance where appropriate and new and innovative solutions such as decentralized trials. Our regulatory and consulting experts — many of whom bring recent FDA and MHRA experience — are here to help as we navigate through this challenging time. Through their expertise we’ve established a COVID-19 Resource Center to provide a centralized repository for global regulatory information and guidance.
To reduce the risk to all of our stakeholders, we have implemented global guidelines limiting travel to business-essential needs only and where permitted based on government authorities. Remote working is not new to us as evidenced by the fact that Parexel recently was named by FlexJobs as a Top 100 company for remote workers for the seventh consecutive year. Our systems and processes are ready to support the transition where needed for our colleagues to deliver services aligned with best practices for virtual working.
In an abundance of caution we have temporarily put a hold on new patient screenings and enrollment in our four global Early Phase Clinical Units across the globe while continuing to support the patients participating in ongoing studies in compliance with CDC guidelines for care in a healthcare setting. Our sites are all part of hospital campuses and have taken added precautions to support patient safety. These units are ready to support the care of patients infected with COVID-19 when and if needed.
At the heart of everything we do are the patients waiting for new therapies. Our focus during this time remains first and foremost on them and the health and well-being of our 20,000 employees worldwide actively working to deliver on their needs. Parexel is contributing actively to the vaccine development efforts for COVID-19 while continuing to develop a broad range of therapies with the potential to change and save patient lives. Our efforts extend beyond our own organization to include collaboration on a harmonized risk-based monitoring approach aligned with regulatory agencies as part of the broader industry response being led through the Association of Clinical Research Organizations (ACRO).
Delivering with heart
As we make every effort to minimize the impact of COVID-19 on our business, we know that there will be challenges and look forward to working through these together and to exploring new approaches for collaboration.
I’d like to thank our colleagues worldwide who continue to keep patient health and the delivery of your needs front and center during this unprecedented time. On behalf of them and our subsidiaries Health Advances, ExecuPharm and The Medical Affairs Company, we thank you for your continued partnership and look forward to our continued focus and collaboration to improve world health.
For questions or additional information on Parexel’s Business Response during this unprecedented time, please reach out to us at firstname.lastname@example.org or visit the COVID-19 Resource Center.
Chief Executive Officer